In conclusion, this study highlights the feasibility and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL, particularly in those without transplant consolidation. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.